Family issues in continuous infusion therapy with factor VIII

Area of Science:

• Hematology
• Pediatric medicine
• Medical technology

Background:

• Recent advances in hemophilia A therapy include recombinant DNA technology for factor VIII (FVIII) production and continuous infusion administration.
• These advancements aim to improve safety by reducing viral transmission risk and optimize pharmacokinetics for cost-effective, sustained FVIII levels.

Purpose of the Study:

• To evaluate the challenges associated with home-based continuous infusion of factor concentrate for hemophilia patients.
• To identify key family and psychosocial factors influencing treatment compliance.
• To outline critical interventions for healthcare providers to support families undergoing aggressive hemophilia therapy.

Main Methods:

• The study reviews clinical trials and therapeutic approaches for hemophilia, focusing on home-based continuous infusion of factor VIII.
• It examines psychosocial factors impacting family functioning and treatment adherence.
• It synthesizes information on essential support strategies for patients and families.

Main Results:

• Home-based continuous infusion of factor concentrate presents significant challenges for parents and children.
• Family factors such as diagnosis acceptance, parenting style, communication, social support, and financial concerns critically affect compliance.
• Perceived benefits and toxicities of the therapy plan also influence adherence.

Conclusions:

• Healthcare providers must recognize and address psychosocial issues to adequately support families with hemophilia.
• Effective interventions include comprehensive family education, support groups, and addressing communication, financial, and disclosure concerns.
• Optimizing family support is essential for the successful implementation of advanced hemophilia treatment plans.